A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL).
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2016 Status changed from recruiting to completed.
- 18 Sep 2013 New trial record